Literature DB >> 8589161

Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin.

J J Cornelissen1, M Rozenberg-Arska, A W Dekker.   

Abstract

To evaluate the mortality and morbidity associated with early discontinuation of intravenously administered antibiotics, we prospectively examined the incidence and cause of recurrent fever in patients with persistent neutropenia who responded to a short course of intravenous antibiotic therapy. Preventive measures included the use of oral ciprofloxacin as prophylaxis for infection by gram-negative bacteria during the entire neutropenic episode. The rate of response to either initial or modified intravenous antibiotic therapy was 96% (149 of 156 episodes of fever). Eighty-five patients had an episode of persistent neutropenia (median duration, 7 days; range, 1-36 days) after they responded to treatment. Seven of these patients had recurrent fever, including 2 with bacteriologically documented infections, 4 with probable fungal pneumonia, and 1 with documented pneumonia due to Aspergillus fumigatus. Two patients with probable fungal pneumonia died, while the other infectious episodes resolved completely. These results do not support the continuation of intravenous antibiotic therapy for febrile patients with persistent neutropenia who have responded to the antibiotic regimen while receiving prophylaxis with oral ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589161     DOI: 10.1093/clinids/21.5.1300

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients.

Authors:  Inge C Gyssens; Winfried V Kern; David M Livermore
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

3.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 4.  Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.

Authors:  Liat Vidal; Itsik Ben Dor; Mical Paul; Noa Eliakim-Raz; Ellisheva Pokroy; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-09

5.  Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.

Authors:  Anat Stern; Elena Carrara; Roni Bitterman; Dafna Yahav; Leonard Leibovici; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2019-01-03

Review 6.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.